4,6-DICHLORO-2-(4-METHOXYBENZYL)PYRIMIDINE, 95%, 1g

6-Fluoropyridine-2-carboxaldehyde, 97.0%, 5g

monoclonal de souris anti-GAPDH, clone 6C5, 0,2 ml

3-Bromo-8-chloro-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, 95.0%, 250mg

ETHYL 7-OXO-4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXYLATE, 95.0%, 250mg

Benzeneacetamide, N-[5-[[7-cyano-2-[(cyclopropylcarbonyl)amino]-6-benzothiazolyl]oxy]-2-fluorophenyl]-3-(trifluoromethyl)-, 100mg

3-(cyclopropylMethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoroMethyl)-[1,2,4]triazolo[4,3-a]pyridine, 10mg

N-Hydroxy-2-(2-methoxy-phenoxy)-acetamidine, 95.0%, 1g

2-Acetyl-7-methoxybenzofuran, 97.0%, 25g

(S)-4-((tert-Butoxycarbonyl)amino)-4-phenylbutanoic acid, 97.0%, 250mg

Récipient de réaction à bride plate, cylindrique, gradué, avec enveloppe de trempe et de vide et vanne de vidange, DN 100, 4000 ml, 250 mm, 1 pièce

N-(4-Bromophenyl-N-(3-cyanophenyl)amine, 97.0%, 1g

1-Hydroxy-naphthalene-2-carboxylic acid hydrazide, 95.0%, 5g